Skip to main content
BCRX logo

BCRX · Biocryst Pharmaceuticals Inc

Track BCRX — free
$7.32 +0.02 (+0.27%)
Market Cap
$1.88B
Shares
257.30M
Volume · Nov 19 3.78M Avg daily vol (3M) 4.93M

Price & Indicators

Close$7.32 Open$7.26 Day$7.20–7.40 52W close$6.24–11.11 Avg vol 30d5.2M Short int27.6M · 10.7% of shares · 5.1d Short vol47% Last earningsNov 4, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 18
Investor event
Full-year guidance of $625 to $645 million tracking upper end

BioCryst expects its guidance of $625 to $645 million for this year to finish at the upper end of that range. Pivotal data covering both 12-month and 6-month results are due to read out in Q3 next year. An update on the Netherton syndrome product is expected within the next few weeks, by the end of this year.

3 source passages
our guidance for this year, $625 to $645 million, at this point, six weeks or so from the end of the year, we expect to end in the upper end of that guidance pivotal data reading out in Q3 of next year for both the 12-month and 6-month results we're excited to report out on our Netherton syndrome product by the end of this year, just in the next few weeks Open the document at this passage
Nov 4
Earnings call
Revenue guidance raised as operating profit jumps 70%

BioCryst raised 2026 total revenue guidance to $715 to $730 million and tightened operating expense guidance to $415 to $425 million; non-GAAP operating profit was $86 million, up 70% year-over-year.

4 source passages
The third quarter was significant for BioCryst as we continue to deliver strong execution during a time of strategic evolution. We are increasing our total revenue guidance to $715 to $730 million, reflecting higher realized licensing revenue and international RAPIWAP orders from our partner. On expenses, we are again tightening our full-year operating expense guidance now to $415 to $425 million for 2026. Non-GAAP operating profit for the quarter was $86 million, an increase of 70% year-over-year, while non-GAAP net income of $71 million more than doubled from the prior year period. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises, but Astria merger charge drives $605.5 million loss

Biocryst Pharmaceuticals Inc reported a $86.7 million increase in total revenue for the nine months ended September 30, 2026, but a $605.5 million net loss driven by a $697.8 million non-cash navenibart charge related to the Astria merger.

Revenue $180.29M ▲ 13.1% Net income $37.92M ▲ 193.9% Diluted EPS $0.14 ▲ 133.3%
Read from the MD&A section
5 source passages
The $86.7 million increase in total revenues for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025 was primarily driven by the following: During the nine months ended September 30, 2026, we incurred a net loss of $605.5 million, which was primarily driven by the non-cash acquired in-process research and development charge of $697.8 million related to the Merger. Acquired in-process research and development expense was $697.8 million for the nine months ended September 30, 2026 related to the non-cash charge recognized for the value assigned to the navenibart in-process research and development asset acquired as part of the Merger. On January 23, 2026, we completed the previously announced merger (the “Merger”) with Astria Therapeutics, Inc. (“Astria”). prior period acceleration of expense pursuant to the BioCryst Pharmaceuticals, Inc. Equity Award Retirement Policy Open the document at this passage
Nov 4
Current report 8-K
Revenue guidance raised as ORLADEYO expands

BioCryst Pharmaceuticals raised full-year 2026 total revenue guidance to $715 million to $730 million, maintained ORLADEYO revenue guidance of $625 million to $645 million, and received FDA approval for ORLADEYO 150 mg oral pellets for patients aged 12 and older.

Financial results, Regulation FD disclosure
2 source passages
The company maintained its outlook for full year 2026 global net ORLADEYO revenue of $625 million to $645 million and increased its full year 2026 total revenue outlook, including revenue from RAPIVAB® (peramivir injection) and the licensing of navenibart European rights, to $715 million to $730 million. Received FDA approval for ORLADEYO 150 mg oral pellets for patients aged 12 and older Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$961.51M
Trailing 12 months
Net income (TTM)
−$359.66M
Trailing 12 months
Revenue growth YoY
+13.1%
Year over year
Operating margin
-30.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
19.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$20.61M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+21.7%
Year over year · more shares
Price change (1Y)
+4.3%
Trailing year
Short interest
10.7%
Latest settlement · 5.1 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. BioCryst reported strong revenue growth, substantially higher profitability and positive cash flow, raised total-revenue guidance, lowered operating-expense guidance and expanded ORLADEYO access. Pipeline readouts remain on track, while risks include a nonrecurring inventory contribution, pharmacy-transition complexity, competition and clinical or regulatory uncertainty.

Bullish
  • + BioCryst generated positive cash flow in Q3 and held $376.4 million of cash, cash equivalents, restricted cash and investments.
Bearish
  • − ORLADEYO revenue received a one-time benefit in the upper teens of millions of dollars from the CareMed inventory build that is not expected to recur each quarter.
  • − The CareMed transition created temporary operational complexity while systems and processes were implemented.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −17%
below
Price vs 50-day avg −10%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 22%
mid-range
Momentum
relative strength
Very Weak
1-month return −6%
trailing
6-month return −15%
trailing
YTD return −6%
this year
Relative strength −9%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $8 › 200d $9 — 200d above 50d
Institutional flow Accumulating
+5% holders QoQ · +52 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.74% of shares out · ▲ +3.9% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
336 holders — near 3-yr high, broad support
Squeeze score 64
elevated · 0–100
Fundamentals
Strong
Revenue growth −4%
Y/Y
EPS growth +381%
Y/Y
Free cash flow $347.0M
Quant / Vol
risk profile
Very High
Volatility 48%
annualized · 1-yr
Max drawdown −34%
past year
ATR 4.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 2
Latest guidance · from the 8-K filed Nov 4, 2026
Total revenue · Full Year 2026 Raised $715M – $730M
Jan 12, 2026 $635M – $660M changed to Nov 4, 2026 $715M – $730M
prior FY $874.84M midpoint −17.4% Y/Y
Non-GAAP operating expense · Full Year 2026 Non-GAAP Raised $415M – $425M
Jan 12, 2026 $380M – $390M changed to Nov 4, 2026 $415M – $425M
Previous outlook earlier release · from the 8-K filed Jan 12, 2026

Still-open targets the latest release did not restate under the same label.

Non-GAAP operating expense including Astria acquisition · full year 2026 $450M – $470M
Guided vs delivered · last 2 settled
Revenue guidance full year
guided $580M – $600M
$874.84M Beat +48.3%
Net revenues full year 2021
guided $115M – $120M
$157.17M Beat +33.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−17% Bearish
Price vs 50-day avg
−10% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
22% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $8 › 200d $9 — 200d above 50d
Institutional flow Accumulating
+5% holders QoQ · +52 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.74% of shares out · ▲ +3.9% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
336 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6 Now $7 · 22% Range high $11
vs 200-day avg -17% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Non-GAAP operating profit non-GAAP $113.2M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BCRX
Biocryst Pharmaceuticals Inc
this stock
$1.88B -6.2% -4.4% — 10.7%
TAK
Takeda Pharmaceutical Co Ltd
$68.40B +37.3% — — 0.1%
GALDY
Galderma Group AG
$51.90B +7.4% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$44.97B +23.5% +4.3% 87.6 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
336
% held
94.8%
Net QoQ
-17.8M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
227
View
Short & Settlement
Short Interest Rising
Shares short
27.6M
Days to cover
5.1d
Change
+1.0M sh
View
Short Volume
Short vol %
47%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
839
Value
$7.0K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
41.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Jul 10, 2026
View
Financials
Financials
Revenue (FY)
$25.2M
Net income (FY)
$263.9M
EPS diluted
$1.21
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
22

BioCryst expects its guidance of $625 to $645 million for this year to finish at the upper end of that range. Pivotal data covering both 12-month and 6-month results are due to read out in Q3 next year. An update on the Netherton syndrome product is expected within the next few weeks, by the end of this year.

View
Proposed Sales
Value
$596.3K
Shares
62.5K
Filed
May 13, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
BioCryst Reports Third Quarter 20…
Published
Nov 4, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
BCRX -4.7% -5.9% -14.6% -13.6% -6.2%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +0.8% +0.4% -9.0% -8.3% -11.1%
Key facts CIK 882796 CUSIP 09058V103 13F (30d) 344 filings 320 filers Visit website Investor relations